ClinicalTrials.Veeva

Menu

Early CPAP in COVID-19 Patients With Respiratory Failure. (EC-COVID-RCT)

M

Mario Negri Institute for Pharmacological Research

Status

Completed

Conditions

COVID-19
CPAP Ventilation
Emergency Departments

Treatments

Device: CPAP treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT04326075
EC-COVID-RCT-Fenice

Details and patient eligibility

About

The study aims at clarifying whether early treatment with continuous positive airway pressure (CPAP) ventilation is able to reduce the need for intubation or death in patients visiting an emergency department (ED) with known or suspected COVID-19 infection and insufficiency respiratory.

Full description

Eligible patients will be randomized to two treatment arms: current clinical practice (control arm) and early treatment with CPAP in addition to current clinical practice (experimental arm). To deal with the current emergency situation, the study will adopt an adaptive design with a Bayesian continuous monitoring. Such design allows to stop the study as soon as the data provide sufficient evidence of efficacy or ineffectiveness of the studied treatment.

The primary endpoint of the study is the combination of intubation or death within 7 days of randomization. The secondary endpoint is 30-day mortality.

All patients arriving at the ED will be evaluated to verify the presence of inclusion and exclusion criteria. Randomization will be performed through an ad-hoc electronic case report form (eCRF). Eligible patients should be randomized as soon as possible, possibly immediately after the ED triage.

Patients randomized to the control arm will be treated according to current clinical practice, which currently does not involve the use of CPAP. Therefore, these patients should not start treatment with CPAP immediately after randomization. CPAP treatment, however, is allowed at a later stage, if deemed appropriate according to clinical judgment.

Patients randomized to the experimental arm should begin treatment with CPAP as soon as possible. CPAP should only be performed with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%. FiO2 and PEEP must be modulated, within the limits indicated above, so as to obtain a saturation > 94%. Whenever this goal cannot be achieved, the patient should be referred to the intensivist.

Enrollment

68 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ED patients positive to or suspected of COVID-19 infection with at least one of the following symptoms:

  • fever
  • cough/dyspnea
  • respiratory symptoms or ED arrival for respiratory reason and for whom there are the following conditions:
  • SpO2 < 95% in ambient air or positive Quick Walk Test
  • PaO2/FiO2 > 200 in ambient air or with Venturi mask, evaluated in 1 hour from ED arrival.

Exclusion criteria

  • BPCO patients
  • Age > 70 years
  • Pregnant status
  • Contraindications for CPAP

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

68 participants in 2 patient groups

Early CPAP treatment
Experimental group
Description:
Early treatment with CPAP in addition to current clinical practice
Treatment:
Device: CPAP treatment
Control
No Intervention group
Description:
Current clinical practice, which currently does not involve the use of CPAP.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems